Publications by authors named "S M Bahr"
Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding.
View Article and Find Full Text PDFArticle Synopsis
- Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease, and the current treatment with Rapamycin only slows its progression, emphasizing the need for new therapeutic options.
- Nitazoxanide (NTZ), a safe and approved drug for treating diarrhea, shows promise due to its mTORC1 inhibitory effect and potential for repurposing in LAM treatment.
- In experiments, NTZ effectively reduced cell growth at specific doses but did not inhibit mTORC1 as expected; it lowered pAkt levels, and while it showed some benefits in reducing lung lesions in mouse models, results need further analysis.
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis catalyzing the tetrahydrobiopterin (BH)-dependent hydroxylation of tyrosine to L-DOPA. Here, we analyzed 25 TH variants associated with various degrees of dopa-responsive dystonia and evaluate the effect of each variant on protein stability, activity and cellular localization. Furthermore, we investigated the physical interaction between TH and human wildtype (wt) GTP cyclohydrolase 1 (GTPCH) and the effect of variants on this interaction.
View Article and Find Full Text PDF